| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Regular Article |
Received December 5, 2001; revised May 1, June 3, 2002; accepted June 19, 2002. From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA (AFS,GMM), Organon Pharmaceuticals, Inc., West Orange, NJ (CK,HER), and The Mirtazapine vs. Paroxetine Study Group. Address correspondence to Dr. Schatzberg, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Room 300, Stanford, CA 94305-5548.
OBJECTIVE: Authors studied the efficacy and tolerability of mirtazapine and paroxetine in elderly patients with major depression during an acute phase (8 weeks) and an extension phase (16 weeks). METHODS: Patients with major depression and without dementia, at least 65 years old, were eligible; they were randomized to mirtazapine or paroxetine once daily, with doses increasing over 42 days. Efficacy was assessed with the Ham-D and Clinical Global Impressions Scale, and tolerability was assessed from adverse events. RESULTS: Of 255 patients randomized, 126 on mirtazapine and 120 on paroxetine were included in the efficacy analysis. Differences favoring mirtazapine were observed for the mean change from baseline in Ham-D–17 score. Other significant differences were in the proportion of patients classified as responders (50% decrease from baseline Ham-D–17 scores) at Day 14 and in remission (Ham-D–17 score of 7 or less) at Day 42. The median time to response was 26 days in the mirtazapine group and 40 days in the paroxetine group. The mirtazapine group also showed more reduction in Ham-D Factor I (Anxiety/Somatization) and Factor VI (Sleep Disturbance) scores. Efficacy of both drugs was maintained during the extension phase. Patients on paroxetine were more likely to discontinue therapy in the acute phase because of adverse events. CONCLUSION: During the first weeks of treatment, antidepressant effects were more pronounced in the mirtazapine group, suggesting that mirtazapine has an earlier onset of action. Mirtazapine also demonstrated a better tolerability profile and represents a valuable option for the treatment of depression in elderly patients.
Key Words: Depression • Paroxetine • Mirtazapine
This article has been cited by other articles:
|
|
 |
|
  J. R. Sneed, B. R. Rutherford, D. Rindskopf, D. T. Lane, H. A. Sackeim, and S. P. Roose Design Makes a Difference: A Meta-Analysis of Antidepressant Response Rates in Placebo-Controlled Versus Comparator Trials in Late-Life Depression Am J Geriatr Psychiatry, January 1, 2008; 16(1): 65 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Boockvar and D. E. Meier Palliative care for frail older adults: "there are things I can't do anymore that I wish I could . . . ". JAMA, November 8, 2006; 296(18): 2245 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Murphy Jr Application of microarray technology in psychotropic drug trials. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 72 - 78. [Abstract] [PDF]
|
|
|
|
|
|
H. K. Gershenfeld, R. A. Philibert, and G. W. Boehm Looking Forward in Geriatric Anxiety and Depression: Implications of Basic Science for the Future Am J Geriatr Psychiatry, December 1, 2005; 13(12): 1027 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hansen, G. Gartlehner, K. N. Lohr, B. N. Gaynes, and T. S. Carey Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder Ann Intern Med, September 20, 2005; 143(6): 415 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Lenze, J. F. Karp, B. H. Mulsant, S. Blank, M. K. Shear, P. R. Houck, and C. F. Reynolds Somatic Symptoms in Late-Life Anxiety: Treatment Issues J Geriatr Psychiatry Neurol, June 1, 2005; 18(2): 89 - 96. [Abstract] [PDF]
|
|
|
|
 |
|
 A. F. Schatzberg Recent Studies of the Biology and Treatment of Depression Focus, January 1, 2005; 3(1): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Fochtmann and A. J. Gelenberg Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition Focus, January 1, 2005; 3(1): 34 - 42. [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Roose, H. A. Sackeim, K. R. R. Krishnan, B. G. Pollock, G. Alexopoulos, H. Lavretsky, I. R. Katz, H. Hakkarainen, and Old-Old Depression Study Group Antidepressant Pharmacotherapy in the Treatment of Depression in the Very Old: A Randomized, Placebo-Controlled Trial Am J Psychiatry, November 1, 2004; 161(11): 2050 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Murphy Jr, S. B. Hollander, H. E. Rodrigues, C. Kremer, and A. F. Schatzberg Effects of the Serotonin Transporter Gene Promoter Polymorphism on Mirtazapine and Paroxetine Efficacy and Adverse Events in Geriatric Major Depression Arch Gen Psychiatry, November 1, 2004; 61(11): 1163 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Murphy Jr., C. Kremer, H. E. Rodrigues, and A. F. Schatzberg Pharmacogenetics of Antidepressant Medication Intolerance Am J Psychiatry, October 1, 2003; 160(10): 1830 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Keller Past, Present, and Future Directions for Defining Optimal Treatment Outcome in Depression: Remission and Beyond JAMA, June 18, 2003; 289(23): 3152 - 3160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Meyers Treatment and Course of Geriatric Depression: Questions Raised by an Evolving Clinical Science Am J Geriatr Psychiatry, October 1, 2002; 10(5): 497 - 502. [Full Text] [PDF]
|
|
|
|
|
|
S. P. Roose and H. A. Sackeim Clinical Trials in Late-Life Depression: Revisited Am J Geriatr Psychiatry, October 1, 2002; 10(5): 503 - 505. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
